[{"address1": "11 Great Valley Parkway", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "484 328 4701", "website": "https://www.ocugen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.", "fullTimeEmployees": 65, "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 1.285, "open": 1.3, "dayLow": 1.28, "dayHigh": 1.35, "regularMarketPreviousClose": 1.285, "regularMarketOpen": 1.3, "regularMarketDayLow": 1.28, "regularMarketDayHigh": 1.35, "beta": 3.8, "forwardPE": -4.5862074, "volume": 16551644, "regularMarketVolume": 16551644, "averageVolume": 8025653, "averageVolume10days": 5498310, "averageDailyVolume10Day": 5498310, "bid": 1.32, "ask": 1.37, "bidSize": 1600, "askSize": 700, "marketCap": 342280832, "fiftyTwoWeekLow": 0.345, "fiftyTwoWeekHigh": 2.105, "priceToSalesTrailing12Months": 51.805786, "fiftyDayAverage": 1.5656, "twoHundredDayAverage": 0.87612, "currency": "USD", "enterpriseValue": 322704352, "floatShares": 253365232, "sharesOutstanding": 257354000, "sharesShort": 52077776, "sharesShortPriorMonth": 45232214, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.2024, "heldPercentInsiders": 0.01582, "heldPercentInstitutions": 0.12832, "shortRatio": 7.11, "shortPercentOfFloat": 0.20549999, "impliedSharesOutstanding": 257354000, "bookValue": 0.118, "priceToBook": 11.271187, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -57676000, "trailingEps": -0.23, "forwardEps": -0.29, "lastSplitFactor": "1:60", "lastSplitDate": 1569801600, "enterpriseToRevenue": 48.843, "enterpriseToEbitda": -5.469, "52WeekChange": 1.7142856, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "OCGN", "underlyingSymbol": "OCGN", "shortName": "Ocugen, Inc.", "longName": "Ocugen, Inc.", "firstTradeDateEpochUtc": 1417617000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "169c2c50-f570-39a4-b709-68c305b79bbd", "messageBoardId": "finmb_303874231", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.33, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.67, "targetMedianPrice": 7.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 26375000, "totalCashPerShare": 0.102, "ebitda": -59003000, "totalDebt": 6832000, "quickRatio": 1.643, "currentRatio": 1.869, "totalRevenue": 6607000, "debtToEquity": 22.577, "revenuePerShare": 0.026, "returnOnAssets": -0.50401, "returnOnEquity": -1.0876, "freeCashflow": -35231000, "operatingCashflow": -54409000, "revenueGrowth": 1.289, "operatingMargins": -12.04734, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]